Salsify Announces Launch of the Salsify PXM Advance Platform, AI-Propelled for the 2nd Decade of the Digital Shelf 21-02-2024, 20:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates 29-03-2024, 11:24